1Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Neonatal Intensive Care Unit, Royal Hospital for Children, Glasgow, UK.
Int Breastfeed J. 2019 Sep 2;14:39. doi: 10.1186/s13006-019-0233-x. eCollection 2019.
Donated human milk (DHM) is a safe alternative in the absence of mother's own milk (MOM); however, specific clinical indications for DHM use and its impact on subsequent feeding practice remain unclear. We aimed to audit local DHM use and explore the impact of the introduction of DHM as the first enteral feed on subsequent MOM availability.
We retrospectively audited DHM recipients nursed in Royal Hospital for Children, Glasgow from 2014 to 2016 against local guidelines. Data were collected from an operational electronic database. Descriptive data analysis was performed to describe DHM use. To explore the association between the first human milk feed with subsequent MOM availability Kruskal Wallis test was used. Adjustments for confounding variables were performed using analysis of variance (ANOVA).
A total of 165 recipients of DHM (5.3% of all admission to RHC) were identified. The majority of recipients (69%) were born < 32 weeks of gestation. The main indication for DHM was prematurity, other indications included congenital anomalies of bowel and heart. The local guideline was adhered to in 87% of cases. The median interquartile range (IQR) at DHM introduction was 6 days (3, 17) and the duration of use was 12 days (6, 22). In those born < 32 weeks of gestation the type of human milk (DHM and/ or MOM) used as first feed did not influence the subsequent median IQR days of feeding with any MOM [DHM 40 (9, 51); MOM 28 (17, 49), MOM & DHM 17 (10, 26) value = 0.465] after adjusting for birthweight and length of hospital stay.
In our unit, DHM is mainly used in preterm neonates in accordance with existing local guidance. Using DHM as first milk feed did not affect subsequent MOM availability.
在缺乏母亲自身母乳(MOM)的情况下,捐献的人乳(DHM)是一种安全的替代物;然而,DHM 使用的具体临床指征及其对后续喂养实践的影响仍不清楚。我们旨在审查当地 DHM 的使用情况,并探讨将 DHM 作为第一肠内喂养物引入对随后 MOM 可用性的影响。
我们对 2014 年至 2016 年在格拉斯哥皇家儿童医院接受 DHM 治疗的患儿进行了回顾性审查,以符合当地的指导方针。数据来自一个操作电子数据库。采用描述性数据分析来描述 DHM 的使用情况。为了探讨第一份人乳喂养与随后的 MOM 可用性之间的关系,我们使用 Kruskal Wallis 检验进行了检验。使用方差分析(ANOVA)进行了混杂变量的调整。
共确定了 165 名接受 DHM 的患儿(所有入住 RHC 的患儿的 5.3%)。大多数患儿(69%)出生时胎龄<32 周。DHM 的主要适应证是早产,其他适应证包括肠和心脏的先天性畸形。87%的病例符合当地指南。DHM 引入时的中位数(IQR)为 6 天(3,17),使用时间为 12 天(6,22)。在出生<32 周的患儿中,作为第一喂养物的人乳类型(DHM 和/或 MOM)并不影响随后任何 MOM 的中位 IQR 喂养天数[DHM 为 40(9,51);MOM 为 28(17,49),MOM & DHM 为 17(10,26),值=0.465],在调整了出生体重和住院时间后。
在我们的单位中,DHM 主要根据现有的当地指导方针用于早产儿。将 DHM 作为第一乳喂养物不会影响随后的 MOM 可用性。